(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are FibroGen, Xenetic Biosciences, and Castle Biosciences.

The three biggest losers today are Brilliant Acquisition Corporation, CareDx, and American Public Education.

Winners today

1. FibroGen (FGEN) – 75.77%

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

NASDAQ ended the session with FibroGen jumping 75.77% to $1.65 on Monday, following the last session’s downward trend. NASDAQ jumped 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around bullish trend exchanging session today.

Earnings Per Share

As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.

Revenue Growth

Year-on-year quarterly revenue growth grew by 155.1%, now sitting on 154.98M for the twelve trailing months.

More news about FibroGen.

2. Xenetic Biosciences (XBIO) – 13.97%

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

NASDAQ ended the session with Xenetic Biosciences rising 13.97% to $3.53 on Monday, following the last session’s downward trend. NASDAQ rose 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -34.98%.

More news about Xenetic Biosciences.

3. Castle Biosciences (CSTL) – 11.75%

Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

NASDAQ ended the session with Castle Biosciences rising 11.75% to $24.28 on Monday while NASDAQ rose 1.12% to $15,628.04.

Earnings Per Share

As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.84.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -18.94%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 66.1%, now sitting on 192.01M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Castle Biosciences’s stock is considered to be oversold (<=20).

Volume

Today’s last reported volume for Castle Biosciences is 178036 which is 30.49% below its average volume of 256134.

More news about Castle Biosciences.

4. Plug Power (PLUG) – 11.06%

Plug Power Inc. delivers end-to-end clean hydrogen and zero-emissions fuel cell solutions for supply chain and logistics applications, on-road electric vehicles, stationary power market, and others in North America and internationally. It engages in building an end-to-end green hydrogen ecosystem, including liquid green hydrogen production, storage and handling, transportation, and dispensing infrastructure. The company offers GenDrive, a hydrogen-fueled proton exchange membrane (PEM) fuel cell system that provides power to material handling electric vehicles; GenFuel, a liquid hydrogen fueling delivery, generation, storage, and dispensing system; GenCare, an ongoing Internet of Things-based maintenance and on-site service program for GenDrive fuel cell systems, GenSure fuel cell systems, GenFuel hydrogen storage and dispensing products, and ProGen fuel cell engines; and GenSure, a stationary fuel cell solution that offers modular PEM fuel cell power to support the backup and grid-support power requirements of the telecommunications, transportation, and utility sectors. It also provides GenKey, an integrated turn-key solution for transitioning to fuel cell power; ProGen, a fuel cell stack and engine technology used in mobility and stationary fuel cell systems, and as engines in electric delivery vans; Liquefaction systems; and Electrolyzers that are hydrogen generators optimized for clean hydrogen production. The company sells its products through a direct product sales force, original equipment manufacturers, and dealer networks. Plug Power Inc. was founded in 1997 and is headquartered in Latham, New York.

NASDAQ ended the session with Plug Power jumping 11.06% to $3.78 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, Plug Power has a trailing twelve months EPS of $-1.6.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.57%.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 15.8% and 25.7%, respectively.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Plug Power’s EBITDA is -17.46.

Yearly Top and Bottom Value

Plug Power’s stock is valued at $3.78 at 16:33 EST, way under its 52-week high of $18.88 and way higher than its 52-week low of $2.26.

More news about Plug Power.

5. Viking Therapeutics (VKTX) – 10.97%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics jumping 10.97% to $23.72 on Monday, following the last session’s downward trend. NASDAQ jumped 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around positive trend exchanging session today.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31.12%.

Moving Average

Viking Therapeutics’s value is way above its 50-day moving average of $17.49 and way higher than its 200-day moving average of $16.48.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Viking Therapeutics’s EBITDA is -26.32.

More news about Viking Therapeutics.

6. Canopy Growth (CGC) – 9.54%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth jumping 9.54% to $5.00 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-15.65.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.66%.

Yearly Top and Bottom Value

Canopy Growth’s stock is valued at $5.00 at 16:33 EST, way below its 52-week high of $32.20 and way above its 52-week low of $3.46.

More news about Canopy Growth.

7. FAT Brands (FAT) – 9.31%

FAT Brands Inc., a multi-brand restaurant company, acquires, develops, markets, and manages quick service, fast casual, casual dining, and polished casual dining restaurant concepts worldwide. It owns restaurant brands, including Round Table Pizza, Marble Slab Creamery, Great American Cookies, Hot Dog on a Stick, Pretzelmaker, Fazoli's, Fatburger, Johnny Rockets, Elevation Burger, Yalla Mediterranean, Buffalo's Cafe and Buffalo's Express, Hurricane Grill & Wings, Ponderosa Steakhouse / Bonanza Steakhouse, Native Grill & Wings, and Twin Peaks. The company was incorporated in 2017 and is headquartered in Beverly Hills, California. FAT Brands Inc. operates as a subsidiary of Fog Cutter Holdings, LLC.

NASDAQ ended the session with FAT Brands jumping 9.31% to $8.10 on Monday, following the last session’s downward trend. NASDAQ rose 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, FAT Brands has a trailing twelve months EPS of $-8.16.

Earnings Before Interest, Taxes, Depreciation, and Amortization

FAT Brands’s EBITDA is 119.15.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Feb 13, 2024, the estimated forward annual dividend rate is 0.56 and the estimated forward annual dividend yield is 7.56%.

Volume

Today’s last reported volume for FAT Brands is 48238 which is 186.36% above its average volume of 16845.

More news about FAT Brands.

8. Nikola (NKLA) – 8.49%

Nikola Corporation operates as a technology innovator and integrator that develops energy and transportation solutions. It operates through two business units, Truck and Energy. The Truck business unit develops and commercializes battery electric vehicles (BEV) and hydrogen fuel cell electric vehicles (FCEV) to the trucking sector. The Energy business unit develops and constructs a network of hydrogen fueling stations; and offers BEV charging solutions for its FCEV and BEV customers, as well as other third-party customers. The company also assembles, integrates, and commissions its vehicles in collaboration with its business partners and suppliers. Nikola Corporation founded in 2015 and is headquartered in Phoenix, Arizona.

NASDAQ ended the session with Nikola rising 8.49% to $0.77 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, Nikola has a trailing twelve months EPS of $-1.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -159.83%.

More news about Nikola.

9. Rumble (RUM) – 7.2%

Rumble Inc. operates video sharing platforms in the United States, Canada, and internationally. The company operates rumble.com, a platform where users can subscribe to channels to stay in touch with creators, and access video on-demand (VOD) and live content streamed by creators. It also operates locals.com, a subscription platform for creators and subscribers to engage through VOD, podcasts, live chat, polls, and community discussions; and Rumble Advertising Center (RAC), an online advertising management exchange. The company was founded in 2013 and is headquartered in Longboat Key, Florida.

NASDAQ ended the session with Rumble jumping 7.2% to $6.47 on Monday, after two consecutive sessions in a row of gains. NASDAQ rose 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Rumble has a trailing twelve months EPS of $-0.42.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -28.68%.

More news about Rumble.

10. Cellectar Biosciences (CLRB) – 7.07%

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

NASDAQ ended the session with Cellectar Biosciences jumping 7.07% to $4.01 on Monday, after two consecutive sessions in a row of gains. NASDAQ jumped 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Cellectar Biosciences has a trailing twelve months EPS of $-3.26.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -435.97%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Cellectar Biosciences’s EBITDA is -2.45.

Yearly Top and Bottom Value

Cellectar Biosciences’s stock is valued at $4.01 at 16:33 EST, under its 52-week high of $4.05 and way above its 52-week low of $1.30.

More news about Cellectar Biosciences.

Losers Today

1. Brilliant Acquisition Corporation (BRLI) – -45.85%

Brilliant Acquisition Corporation does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company was incorporated in 2019 and is based in Shanghai, China.

NASDAQ ended the session with Brilliant Acquisition Corporation sliding 45.85% to $4.70 on Monday, after five sequential sessions in a row of losses. NASDAQ jumped 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Brilliant Acquisition Corporation has a trailing twelve months EPS of $-0.25.

More news about Brilliant Acquisition Corporation.

2. CareDx (CDNA) – -17.32%

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

NASDAQ ended the session with CareDx sliding 17.32% to $9.02 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, CareDx has a trailing twelve months EPS of $-1.69.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -21.79%.

Sales Growth

CareDx’s sales growth is negative 24% for the ongoing quarter and negative 20.1% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 15.3%, now sitting on 297.14M for the twelve trailing months.

Volume

Today’s last reported volume for CareDx is 3942330 which is 208.27% above its average volume of 1278830.

Yearly Top and Bottom Value

CareDx’s stock is valued at $9.02 at 16:33 EST, way under its 52-week high of $18.04 and way above its 52-week low of $4.80.

More news about CareDx.

3. American Public Education (APEI) – -13.41%

American Public Education, Inc., together with its subsidiaries, provides online and campus-based postsecondary education and career learning. It operates through three segments: American Public University System, Rasmussen University, and Hondros College of Nursing. The company offers 136 degree programs and 115 certificate programs in various fields of study, including nursing, public health, public administration, and business administration. It also provides nursing-and health sciences-focused postsecondary education, diploma in practical nursing, and an associate degree in nursing. The company was incorporated in 1991 and is headquartered in Charles Town, West Virginia.

NASDAQ ended the session with American Public Education sliding 13.41% to $10.27 on Monday, following the last session’s downward trend. NASDAQ jumped 1.12% to $15,628.04, following the last session’s downward trend on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, American Public Education has a trailing twelve months EPS of $-3.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -22.4%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.9%, now sitting on 600.18M for the twelve trailing months.

Volume

Today’s last reported volume for American Public Education is 264118 which is 142.14% above its average volume of 109073.

Moving Average

American Public Education’s worth is way higher than its 50-day moving average of $9.16 and way higher than its 200-day moving average of $6.15.

More news about American Public Education.

4. CASI Pharmaceuticals (CASI) – -10.83%

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.

NASDAQ ended the session with CASI Pharmaceuticals sliding 10.83% to $7.00 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, CASI Pharmaceuticals has a trailing twelve months EPS of $-3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -59.42%.

More news about CASI Pharmaceuticals.

5. iRobot (IRBT) – -9.21%

iRobot Corporation designs, builds, and sells robots and home innovation products in the United States, Europe, the Middle East, Africa, Japan, and internationally. The company offers floor care products, including Roomba floor vacuuming robots; Roomba accessories and consumables, such as the Clean Base Automatic Dirt Disposal, replacement dirt disposal bags for the Clean Base, filters, brushes, and batteries; Braava family of automatic floor mopping robots; and Braava accessories and consumables, which include cleaning solution, washable and disposable mopping pads, replacement tanks, and batteries, as well as subscription services. It also provides H1 Handheld Vacuum, a portable vacuum; H1 Handheld Vacuum accessories comprising filters, chargers, batteries, and an extension kit that converts the H1 Handheld Vacuum into a stick vacuum; air purifiers under the Aeris brand; Root robots to help children learn how to code; and Create 3, a mobile robot platform that offers an opportunity for educators, developers, and high-school and college students to program behaviors, sounds, movements, and add additional electronics, as well as sells filters and fabric covers. The company sells its products through chain stores and other national retailers, distributors, and resellers, as well as through its website and app, and e-commerce websites. iRobot Corporation was incorporated in 1990 and is headquartered in Bedford, Massachusetts.

NASDAQ ended the session with iRobot falling 9.21% to $15.43 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, iRobot has a trailing twelve months EPS of $-11.81.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

iRobot’s EBITDA is -19.4.

More news about iRobot.

6. Lumen Technologies (LUMN) – -8.93%

Lumen Technologies, Inc., a facilities-based technology and communications company, provides various integrated products and services under the Lumen, Quantum Fiber, and CenturyLink brands to business and residential customers in the United States and internationally. The company operates in two segments, Business and Mass Markets. It offers compute and application services, such as edge cloud services, IT solutions, unified communication and collaboration solutions, colocation and data center services, content delivery services, and managed security services; and IP and data services, including VPN data network, Ethernet, internet protocol (IP), and voice over internet protocol. The company also provides fiber infrastructure services comprising high bandwidth optical wavelength networks; and unlit optical fiber and related professional services. In addition, it offers voice and other services, including private line services, a direct circuit or channel specifically dedicated for connecting two or more organizational sites; a portfolio of traditional time division multiplexing voice services; and synchronous optical network-based ethernet, legacy data hosting services, and conferencing services. The company was formerly known as CenturyLink, Inc. and changed its name to Lumen Technologies, Inc. in September 2020. The company was incorporated in 1968 and is headquartered in Monroe, Louisiana.

NYSE ended the session with Lumen Technologies sliding 8.93% to $1.28 on Monday, after four consecutive sessions in a row of gains. NYSE rose 0.41% to $17,018.74, after two sequential sessions in a row of gains, on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Lumen Technologies has a trailing twelve months EPS of $-11.49.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -153.72%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Lumen Technologies’s stock is considered to be oversold (<=20).

Revenue Growth

Year-on-year quarterly revenue growth declined by 17.1%, now sitting on 14.84B for the twelve trailing months.

Volume

Today’s last reported volume for Lumen Technologies is 20258300 which is 10.51% above its average volume of 18330500.

More news about Lumen Technologies.

7. Pinduoduo (PDD) – -7.92%

PDD Holdings Inc., a multinational commerce group, owns and operates a portfolio of businesses. It operates Pinduoduo, an e-commerce platform that offers products in various categories, including agricultural produce, apparel, shoes, bags, mother and childcare products, food and beverage, electronic appliances, furniture and household goods, cosmetics and other personal care, sports and fitness items and auto accessories; and Temu, an online marketplace. It focuses on bringing businesses and people into the digital economy. The company was formerly known as Pinduoduo Inc. and changed its name to PDD Holdings Inc. in February 2023. PDD Holdings Inc. was incorporated in 2015 and is based in Dublin, Ireland.

NASDAQ ended the session with Pinduoduo dropping 7.92% to $130.54 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Earnings Per Share

As for profitability, Pinduoduo has a trailing twelve months EPS of $4.45.

PE Ratio

Pinduoduo has a trailing twelve months price to earnings ratio of 29.34. Meaning, the purchaser of the share is investing $29.34 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 34.33%.

Sales Growth

Pinduoduo’s sales growth is 95% for the current quarter and 113.8% for the next.

More news about Pinduoduo.

8. Clean Diesel Technologies (CDTI) – -6.45%

CDTi Advanced Materials, Inc. provides technology and solutions to the automotive emissions control markets in the United States, Canada, and Europe. Its catalyst products include synergized- platinum group metal (PGM) diesel oxidation catalysts, zero-PGM catalysts, selective catalytic reduction catalysts, and base-metal activated rhodium support catalysts. The company supplies its coated substrates directly to exhaust systems manufacturers; and catalyst technologies to automakers, heavy duty truck manufacturers, catalyst manufacturers, distributors, integrators, and retrofitters. CDTi Advanced Materials, Inc. was founded in 1996 and is headquartered in Oxnard, California.

NASDAQ ended the session with Clean Diesel Technologies falling 6.45% to $0.58 on Monday while NASDAQ rose 1.12% to $15,628.04.

Earnings Per Share

As for profitability, Clean Diesel Technologies has a trailing twelve months EPS of $-0.97.

Sales Growth

Clean Diesel Technologies’s sales growth is negative 70.5% for the present quarter and negative 38.6% for the next.

Volume

Today’s last reported volume for Clean Diesel Technologies is 3088 which is 21.76% above its average volume of 2536.

Moving Average

Clean Diesel Technologies’s worth is below its 50-day moving average of $0.60 and way higher than its 200-day moving average of $0.49.

More news about Clean Diesel Technologies.

9. First Majestic Silver (AG) – -5.45%

First Majestic Silver Corp. engages in the acquisition, exploration, development, and production of mineral properties with a focus on silver and gold production in North America. Its projects include the San Dimas mine that consists of 119 individual concessions covering an area of 71,839 hectares located in Durango and Sinaloa States, México; the Santa Elena comprising 32 individual concessions that covers an area of 102,172 hectares located in Sonora State, México; and the La Encantada consists of 22 exploitation concessions covering an area of 4,076 hectares located in Coahuila State, México. The company was formerly known as First Majestic Resource Corp. and changed its name to First Majestic Silver Corp. in November 2006. First Majestic Silver Corp. was incorporated in 1979 and is headquartered in Vancouver, Canada.

NYSE ended the session with First Majestic Silver falling 5.45% to $4.60 on Monday, following the last session’s downward trend. NYSE rose 0.41% to $17,018.74, after two sequential sessions in a row of gains, on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, First Majestic Silver has a trailing twelve months EPS of $-0.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -12.08%.

Volume

Today’s last reported volume for First Majestic Silver is 14691600 which is 123.72% above its average volume of 6566730.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Nov 13, 2023, the estimated forward annual dividend rate is 0.02 and the estimated forward annual dividend yield is 0.43%.

More news about First Majestic Silver.

10. Koninklijke Philips (PHG) – -5.4%

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. The company provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease; proprietary software to enable diagnostics and intervention; and enterprise diagnostic informatics products and services. It also offers acute patient management solutions; emergency care solutions; sleep and respiratory care solutions; and electronic medical record and care management solutions. In addition, the company provides power toothbrushes, brush heads, and interdental cleaning and teeth whitening products; infant feeding, baby monitors, and digital parental solutions; and grooming and beauty products and solutions. It has strategic partnership agreements with TriHealth, Prisma Health, and the University Health System of San Antonio to help the health system standardize patient monitoring, drive interoperability, and lay the foundation for enterprise-wide platform; and Oulu University Hospital to deliver advanced image-guided therapy solutions. The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.

NYSE ended the session with Koninklijke Philips dropping 5.4% to $21.53 on Monday, after two consecutive sessions in a row of losses. NYSE rose 0.41% to $17,018.74, after two successive sessions in a row of gains, on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Koninklijke Philips has a trailing twelve months EPS of $-0.64.

Yearly Top and Bottom Value

Koninklijke Philips’s stock is valued at $21.53 at 16:33 EST, way under its 52-week high of $24.27 and way higher than its 52-week low of $15.63.

More news about Koninklijke Philips.

Stay up to date with our winners and losers daily report